# Mariana Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mariana-oncology

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.marianaoncology.com
- Total disclosed funding: $250M
- Latest round: Series B (Sep 7, 2023)
- Investors on record: 8

## About

Based in Massachusetts, US, and founded in 2021 by its CEO, Simon Read, Curie Therapeutics, Inc., trading as Curie, is a biotechnology company that provides radiopharmaceuticals for the treatment of tumors. In September 2023, Mariana Oncology, Inc. raised USD 170 million in series B funding co-led by Deep Track Capital and Forbion, with participation from Eli Lilly & Company, Nextech, and Surveyor Capital. Returning investors Access Industries, Atlas Venture, and RA Capital Management also participated in the round.

Curie Therapeutics, Inc. develops integrated radiopharmaceuticals that are used to diagnose solid cancers and deliver radiation directly to disease sites. Curie ligands are designed to allow deeper, more homogeneous tumor distribution as well as rapid systemic clearance. Curie’s macrocyclic peptide-based drug targets extracellular domains. Curie uses both alpha and beta-emitting radionuclides to address significant therapeutic needs in solid tumor biology.

The company will use the series B funding to support the development of its portfolio.

## Funding rounds

- Series B, Sep 7, 2023, $175M — Atlas Venture, Access Industries, Forbion, Nextech, Eli Lilly & Company, RA Capital Management, Surveyor Capital, Deep Track Capital
- Series A, Dec 1, 2021, $75M — Atlas Venture, Access Industries, RA Capital Management

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Eli Lilly & Company — Series B
- Surveyor Capital — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B